BofA lowered the firm’s price target on Inozyme to $14 from $16 and keeps a Buy rating on the shares after the company reported topline results for the Phase 1/2 trials evaluating INZ-701 in ABCC6 and ENPP1 deficiency adult patients. While “encouraged” by the early data that the firm thinks is suggestive of a path forward for the program, BofA notes the data was in a small number of patients and “would like to hear more about FDA’s views.” The firm now models a late-2027 pediatric ABCC6 U.S. launch estimate, pushed out from a prior view of 2026, which lowers its price target by $2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Advances with Promising INZ-701 Trial Results
- Inozyme announces ‘positive’ results from Phase 1/2 trials of INZ-701
- Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference